Autopsy report · NCT02753595

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

“evolving standard of care and difficulties of enrolling participants”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 25 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Eisai Inc.

Sponsor type

Industry

Conditions

Metastatic Breast Cancer

Interventions

Eribulin mesylate; Eribulin mesylate; Eribulin mesylate; Biologic: PEGylated recombinant human hyaluronidase (PEGPH20); Biologic: PEGylated recombinant human hyaluronidase

Participants

25

Sites

7

Countries

United States

Trials that died the same way

• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
  “difficulty of enrolling patients” (74% match in meaning)
• Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
  “Lack of enrollment and changing landscape of standard of care.” (72% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (71% match in meaning)
• Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project
  “Severe difficulties in enrolling individuals” (69% match in meaning)
• Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
  “because of difficulties of enrolling appropriate participants” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.